Objective Patients with type 2 diabetes mellitus (T2DM) and peripheral arterial disease are classified as having very high cardiovascular risks. We therefore sought to determine whether assessments of the ankle brachial index (ABI) and brachial ankle pulse wave velocity (baPWV) together exhibited a superior association with the outcomes of T2DM. Methods A retrospective analysis of patients receiving ABI and baPWV during the period 2005-2007 was performed. Patients A total of 452 subjects were enrolled and followed-up for a mean 5.8 years after being grouped according to the ABI (<0.9 vs. ! 0.9) and baPWV (<1,700 cm/s vs. ! 1,700 cm/s). Results The outcomes were all-cause mortality and composite events (all-cause mortality, hospitalization for coronary artery disease, stroke, re-vascularization, amputation and diabetic foot). Inter-group differences in the smoking rate, duration of diabetes, systolic and pulse blood pressure, anti-platelet drugs, estimated glomerular filtration rate, and urine albumin excretion were significant. During the follow-up period, 17 (3.7%) individuals died and composite events were recorded in 64 cases (14.1%). A low ABI plus high baPWV was found be associated with poor outcomes compared with a normal ABI plus low baPWV (p< 0.001). Meanwhile, a low ABI plus high baPWV was associated with an increased risk of all-cause mortality [hazard ratio (HR) 17.01, 95% confidence interval (CI) 1. 57-183.73, p=0.019] and composite events (HR 8.53, p<0.001). Conclusion In this study, the outcomes of patients with a low ABI plus high baPWV were the worst, while the subjects with a low ABI plus low baPWV or normal ABI exhibited similar outcomes. Therefore, the ABI plus baPWV exhibits a better association with the outcomes of T2DM.
Introduction
Worldwide, diabetes mellitus affected 371 million people in 2012; this number is expected to rise to 552 million by 2030 (1, 2) . Type 2 diabetes mellitus (T2DM) is considered to be an independent risk factor for coronary artery disease and its equivalents, including peripheral artery disease (PAD), the risk of which is doubled in diabetic patients (3) (4) (5) . PAD is also associated with a higher grade Killip class of myocardial infarction without ST elevation and greater incidence of in-hospital events, such as death, shock, recurrent angina, and stroke (6) . Overall, patients with type 2 diabetes and PAD are classified as belong to the very-high risk group, with a 10-year cardiovascular risk of more than 20%, according to the third report of the National Cholesterol Education Program Adult Treatment Panel (NCEP-ATP III) (7) .
PAD is diagnosed based on an ankle brachial index (ABI), calculated as the ratio of the systolic blood pressure of the ankle to that of the arm, of less than 0.9 (8) . The ABI is also an independent predictor of cardiovascular and cerebrovascular events (9) . However, the association between the ABI and the outcomes of type 2 diabetes is uncertain. One study showed an abnormal ABI to be a predictor of recurrent cardiovascular events and all-cause mortality in nondiabetic, but not diabetic, patients. The authors proposed that diabetes is an established risk factor and that the ABI does not provide additional prognostic value (10) . Furthermore, another prospective analysis demonstrated that the association between the ABI and the prognosis did not differ between non-diabetic and diabetic patients with an ABI of < 0.9 and may be the results of overestimation of the ABI values in diabetic patients with vascular calcification (11) . Moreover, the ABI values may be under-estimated in hypertensive patients (12) . Hence, the ABI alone may not exhibit a perfect association with the outcomes of diabetic patients.
An abnormal brachial ankle pulse wave velocity (baPWV), a measurement of arterial stiffness, is also associated with adverse cardiovascular outcomes (13, 14) . The ability of this parameter to identify arteriosclerosis and atherosclerosis and its close correlation with the Framingham risk score support its use in addition to the ABI (15) . The aim of this study was therefore to investigate whether the combination of ABI and baPWV correlates more closely with cardiovascular outcomes in diabetic patients.
Materials and Methods

Patient population and clinical data
This was a retrospectively chart review study. Ethics approval was provided by Taipei Veterans General Hospital, Taiwan (VGHIRB No.: 2012-07-029BC). The demographic and anthropometric characteristics, coronary artery disease (CAD) or cerebrovascular disease history, ABI and baPWV values and medication history of type 2 diabetic patients who visited the division of endocrinology and metabolism at Taipei Veterans General Hospital between July, 2005 and December, 2007 were reviewed. The exclusion criteria were as follows: (1) loss to follow-up in our hospital for more than six months; (2) a status of post-below knee amputation; (3) previously diagnosed PAD; (4) missing important covariates; (5) poor glycemic control, with a hemoglobin A1C (HbA1C) value above 10%; (6) an ABI above 1.4. All ABI and baPWV measurements were recorded using an Omron non-invasive vascular screening device (VP-1000, Omron Healthcare Company, Kyoto, Japan) for the purpose of screening for PAD. The pulse pressure was defined as the difference between the systolic and diastolic blood pressure. The body mass index was calculated as the weight (kg) divided by the square of the height (meters). Laboratory results obtained within three months of ABI/baPWV measurement, including fasting plasma glucose, HbA1C, serum creatinine, estimated glomerular filtration rate (eGFR) calculated according to the formula of the Modification of Diet in Renal Disease (MDRD), 24-hour urine albumin excretion, and lipid profiles, were recorded.
Groups and outcome definition
The enrolled patients were divided into four groups according to the combination of ABI (<0.9 or ! 0.9) and baPWV (<1,700 cm/s or ! 1,700 cm/s). Individuals with an ABI less than 0.9 were considered to be diagnosed with PAD, which is associated with a worse cardiovascular prognosis. The rationale for the cut-off point for baPWV which was set at 1,700 cm/s, was based on the results by Hirufumi et al, whose analysis revealed baPWV to be a predictor of the prognosis of subjects with acute coronary syndrome, with a baPWV above 1,700 cm/s being the best cut-off point for predicting post-hospitalization cardiovascular events (14) . The outcomes up to August, 2012 were retrospectively reviewed. The primary outcome was all-cause mortality, and the secondary outcomes were composite events, including all-cause mortality, hospitalization for CAD, stroke, carotid or peripheral revascularization, lower limb amputation and hospitalization for diabetic foot.
Statistics
Continuous variables are expressed as the mean±standard deviation (SD) and were compared using an independent ANOVA test. The categorical variables are expressed as numbers and percentages and were compared using the Pearson chi-square test. The cumulative event-free probabilities of the primary and secondary outcomes were estimated using a Kaplan-Meier analysis. The log-rank test was used to identify significant differences. All relevant variables were tested according to a univariate Cox proportional analysis, and those with a p value <0.1 were further subjected to a multivariate Cox proportional analysis in which the hazard ratio (HR) with corresponding probability values were calculated. The SPSS software package (version 18, IBM Corpo- .05 was defined as significant difference among four groups *ABI<0.9 plus baPWV 1,700 cm/s vs. ABI 0.9 plus baPWV 1,700 cm/s, p=0.04; ABI<0.9 plus baPWV 1,700 cm/s vs. ABI 0.9 plus baPWV<1,700 cm/s, p=0.003 †ABI<0.9 plus baPWV 1,700 cm/s vs. ABI 0.9 plus baPWV 1,700 cm/s, p<0.001; ABI 0.9 plus baPWV 1,700 cm/s vs. ABI 0.9 plus baPWV<1,700 cm/s, p<0.001 ‡ ABI<0.9 plus baPWV 1,700 cm/s vs. ABI 0.9 plus baPWV<1,700 cm/s, p=0.012 §ABI<0.9 plus baPWV 1,700 cm/s vs. ABI 0.9 plus baPWV<1,700 cm/s, p=0.012 || ABI 0.9 plus baPWV<1,700 cm/s vs. ABI<0.9 plus baPWV<1,700 cm/s, p=0.003 ACEI: angiotensin converting enzyme inhibitor, ARB: angiotensin II receptor blockade, ABI: ankle brachial index, baPWV: brachial ankle pulse wave velocity ration, Armonk, USA) was used for the data analysis.
Results
Baseline characteristics
We reviewed 517 patients, of whom 65 individuals were excluded (28 due to loss to follow-up for more than six months, two for a status of post-below knee amputation, six for previously diagnosed PAD, 18 for missing co-variates, and 11 for a HbA1C level of >10%). We analyzed the charts of 452 subjects with type 2 diabetes who were followed up for a mean duration of 5.8 years. Tables 1 and 2 show the baseline characteristics of the four groups. There were 95 patients in the group with an ABI of ! 0.9 and baPWV of < 1,700 cm/s, 297 in the group with an ABI of ! 0.9 and baPWV of ! 1,700 cm/s, 21 in the group with an ABI of < 0.9 and baPWV of <1,700 cm/s and 39 in the group with an ABI of <0.9 and baPWV of ! 1,700 cm/s. There were no significant differences between the four groups in terms of history of smoking, the duration of diabetes, systolic blood pressure, pulse pressure, use of anti-platelet drugs, eGFR and 24-hour urine albumin excretion. In contrast, the percentage of smokers was higher and the mean duration of diabetes was longer in the group with an ABI of <0.9 and baPWV of ! 1,700 cm/s than in the group with an ABI of ! 0.9 (p<0.05). In addition, the mean systolic blood pressure, pulse pressure and 24-hour urine albumin excretion were higher, while the eGFR was lower, in the group with an ABI of <0.9 and baPWV of ! 1,700 cm/s than in the group with an ABI of ! 0.9 and baPWV of <1,700 cm/s (p<0.05), whereas the frequency of anti-platelet drug use was significantly higher in the group with an ABI of ! 0.9 and baPWV of ! 1,700 cm/s than in the group with an ABI of <0.9 and baPWV of <1,700 cm/s (52.3% vs. 23.5%, p=0.003). There were no differences in baseline characteristics between the two groups with an ABI of <0.9.
Primary outcome
Seventeen subjects died before the end of the follow-up period in this study. Nine (52.9%) of these patients died due to cardiovascular events (seven from coronary artery disease and two from stroke) and four (23.5%) died due to being in the terminal stage of malignant disease (two with pulmonary carcinoma, one with pancreatic carcinoma and one with hepatocarcinoma). The remaining mortalities were due to other diseases (one case of necrotizing fasciitis, two cases of pneumonia and one case of peptic ulcer bleeding). All-cause mortality was significantly higher among the patients with an ABI of <0.9 than in those with an ABI of ! 0.9 (23.0% vs. 2.0%, p<0.001) ( Figure A, Table 3 ). The Kaplan-Meier analysis showed that the patients with an ABI of <0.9 and baPWV of ! 1,700 cm/s had significantly higher all-cause mortality rates than those with an ABI of ! 0.9 and baPWV of <1,700 cm/s (23.0% vs. 3.1%, p<0.001) ( Figure B, Table 3 ). In addition, the univariate Cox-regression test showed that in the group with an ABI of <0.9 and baPWV of ! 1,700 cm/s, age, a history of smoking, pulse pressure, duration of diabetes, low-density lipoprotein cholesterol (LDL-C) and eGFR were each associated with all-cause mortality (Table 4) . After adjusting for these factors and other conventional cardiovascular risk factors in a multivariate Cox regression analysis, the combination an ABI of <0.9 and baPWV of ! 1700 cm/s was found to be a more predominant risk factors for all-cause mortality [hazard ratio (HR) 17.01, 95% confidence interval (CI) 1.57-183.73, p= 0.019] than age or LDL-C (Table 4) .
Secondary outcomes
The patients with an ABI of <0.9 had higher composite events rates than those with an ABI of ! 0.9 (55.0% vs. 10.4%, p<0.001) ( Figure C) and those with an ABI of <0.9 and baPWV of ! 1,700 cm/s had poorer secondary outcomes than those with an ABI of ! 0.9 and baPWV of <1,700 cm/s (43.5% vs. 8.4%, p<0.001) ( Figure D) . Among the patients with an ABI of <0.9, those with a baPWV of ! 1,700 cm/s had higher composite events rates than those with a baPWV of <1,700 cm/s (43.5% vs.19.0%, p=0.019) ( Figure D , Table 4). Meanwhile, the rates of hospitalization for CAD and carotid or peripheral revascularization were higher in the group with an ABI of <0.9 and baPWV of ! 1,700 cm/s than in the group with an ABI of ! 0.9 and baPWV of <1,700 cm/s (20.5% vs.5.2%, p<0.001 for hospitalization for CAD; 10.2% vs. 0%, p<0.001 for peripheral revascularization) (Table 3). Furthermore, the univariate Cox regression analysis showed an ABI of <0.9 and baPWV of ! 1,700 cm/s, age, the duration of diabetes, history of CAD, eGFR and use of statins to be significantly associated with composite events (Table 4) . After adjusting for these factors, the multivariate Cox regression analysis showed an ABI of <0.9 and baPWV of ! 1,700 cm/s to be associated with more composite events (HR 8.53, 95% CI 3.31-21.99, p<0.001) than eGFR or a 
Discussion
In the present study, the combination of the ABI and baPWV was found to be associated with cardiovascular outcomes in diabetic patients. Although an ABI less than 0.9 is sensitive for diagnosing PAD, it has been demonstrated to have a weaker association with outcomes in patients with diabetes than in those without, in contrast to risk stratification according to NCEP-ATP III (6) . The weaker association between ABI and outcomes observed in diabetic patients let us to hypothesize that the addition of baPWV, which is associated with the cardiovascular prognosis in different patient groups, may help to distinguish heterogeneous associations in diabetic patients (16, 17) . Consequently, the present data analysis revealed that the rate of composite events was significantly higher in the diabetic patients with a low ABI and high baPWV than in those with a low ABI and low baPWV; a similar trend was also observed for all-cause mortality. The results of this study thus support the hypothesis regarding the presence of a heterogeneous association in diabetic patients with an ABI less than 0.9, such that the combination of ABI and baPWV provides more information about the outcomes of diabetic patients.
In addition, patients with an ABI less than 0.9 and baPWV more than 1,700 cm/s exhibited higher systolic blood pressure and pulse pressure values and rates of smoking as well as longer duration of diabetes. These findings agree with those of previous investigations showing that hypertension and smoking are both predictors of the progression of peripheral vascular disease, following the generation of atherosclerotic plaques in medium-sized arteries (18) . Hence, the rapid progression of atherosclerosis due to high blood pressure, smoking, and a longer duration of diabetes was found to be associated with the ABI and baPWV in this study. Although these factors are also well-recognized cardiovascular risk factors, a low ABI concomitant with a high baPWV was shown to be predominantly associated with the outcomes of the diabetic patients after adjusting for confounders in the multivariate Cox proportional hazard model.
The eGFR was also found to be inversely associated with all-cause mortality and composite events in this study and a low eGFR values were noted in patients with an ABI below 0.9 and baPWV above 1,700 cm/s. Chronic kidney disease (CKD), defined as an eGFR less than 60 mL/min according to the MDRD equation, is considered a cardiovascular risk factor, as has been demonstrated in patients in the early stages of CKD (19) . Therefore, the association between eGFR and outcomes noted in this study is compactible with the finding of the above investigation. Furthermore, a previous study showing an association between higher baPWV values and lower eGFR values suggested a bidirectional cause-and-effect relationship between arterial stiffness and renal dysfunction (20) . CKD increases arterial stiffness via vascular calcification, endothelial dysfunction, chronic volume overload, inflammation and oxidative stress, while and arterial stiffness hastens the onset of renal dysfunction via the loss of compliance of the large arteries due to adaptions to pulsations following left ventricular ejection (21, 22) .
Moreover, the LDL-C level was found to be inversely associated with all-cause mortality rate in this study. This re-sult may be explained by the J-or U-shaped relationship between LDL-C and mortality. A similar trend of association due to smoking-related cancer death was also recently reported in a prospective epidemiological study (23) . Current research has revealed that smoking reduces the total cholesterol, high-density lipoprotein cholesterol, and LDL-C concentrations, as well as the level of coenzyme Q10, an antioxidative factor effective in blocking the formation of atheromatous plaque (24) . In addition, a J-shaped relationship between LDL-C and mortality was recently indentified in a primary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT), in which patients were treated with simvastatin. Hyper-responsiveness to simvastatin is thought to be responsible for this relationship via unknown mechanisms (25) . In the present study, we noted a higher rate of smoking in the group with an ABI of <0.9 and baPWV of ! 1,700 cm/s, suggesting that smoking may be the initial causative factor for the inverse association between LDL-C and all-cause mortality. Statin therapy was employed in onefourth of the patients in this study without significant intergroup differences; therefore, hyper-responsiveness to statin therapy in some patients is the second possible explanation.
The results for baPWV tended to be under-estimated when the ABI was less than 0.9. Hence, more severe atherosclerosis and worse outcomes may be predicted in patients with an ABI below 0.9 than in those with an ABI above 0.9, with the same baPWV. The predictive value of baPWV was compatible bwteen the two groups, such that any underestimation of this parameter may not have exerted a significant influence on the findings when combined with the ABI values.
Although statin use decreased the rate of composite events by 43% in this study, the insignificant difference in outcomes between the diabetic patients with an ABI less than 0.9 and low baPWV and those with an ABI more than 0.9 and the inverse relationship between the LDL-C level and outcomes, suggest the need for a less stringent therapeutic goal for dyslipidemia patients with an ABI less than 0.9 and low baPWV. The Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT) trial demonstrated the survival benefit of intensive blood lipid control in patients with a recent history of acute coronary syndrome (26) , and the NCEP-ATPIII suggests a more stringent goal for LDL-C (less than 70 mg/dL) in patients with a very high cardiovascular risk (27) . Furthermore, diabetic patients with PAD, who are classified into the very-high risk group, require higher doses of statins to achieve optimal LDL-C levels, albeit with an increased risk of adverse muscle effects (27, 28) . Hence, the benefits and risks of statin therapy should be considered in patients with an ABI less than 0.9 and low baPWV.
Measurement of the ABI plus baPWV is not the only non-invasive method for evaluating the cardiovascular prognosis. Another popular parameter, the carotid-intima media thickness (cIMT) and/or carotid-intima media thickness variability (IMTV), is widely used as a risk factor in different populations. The cIMT may be used to predict the probability of cardiovascular events, such as non-fatal myocardial infarction (29) , while the cIMT and carotid plaque score have been shown to be predictors for stroke and mortality in subjects with hypertension (30) . However, Kawai et al validated that the efficacy of predicting cardiovascular events based on the cIMT is inferior that of the plaque score, which exhibits greater accuracy in prediction and is equivalent to the pulse wave velocity (30) . In addition, Ikeda et al. demonstrated the results of a cohort study of 500 Japanese patients in which the IMTV was found to be better associated with the existence of coronary artery disease than the cIMT, and the IMTV, not cIMT, was shown to correlate with the ABI (31) . Consequently, the ABI and/or pulse wave velocity may be superior parameters in terms of their association with the outcomes of cardiovascular disease than the cIMT. In the present study, compared with the ABI alone, a better association with the cardiovascular prognosis was observed for the combination of ABI and baPWV. In conclusion, the ABI plus baPWV may not be inferior to the cIMT alone.
Various limitations are associated with the present study. For examples, there was no non-diabetic control group and a single-center retrospective study cannot avoid selection bias. Furthermore,the numbers of diabetic patients with an ABI less than 0.9 may have been too small to be representative of the general population, and the medical history and events of the subjects not included in the medical records may have induced bias into the analysis.
Conclusion
The combination of ABI and baPWV exhibits a superior association with the prognosis in diabetic patients than the ABI alone. Further studies are required to investigate whether the combination of ABI and baPWV can be used to guide treatment decisions.
The authors state that they have no Conflict of Interest (COI).
